Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-HER2 ribozyme - Elan/Sirna

Drug Profile

Anti-HER2 ribozyme - Elan/Sirna

Alternative Names: Anti-HER2 ribozyme - Elan/Sirna; Herzyme

Latest Information Update: 08 Jan 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elan Pharmaceutical Technologies; Sirna Therapeutics
  • Developer Sirna Therapeutics
  • Class Antineoplastics; Ribozymes
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
  • 22 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the adverse events and pharmacokinetics section
  • 17 Apr 2003 Ribozyme Pharmaceuticals is now called Sirna Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top